Loading clinical trials...
Loading clinical trials...
The purpose of the study is to learn more about health care providers' experiences and perspectives on prescribing HIV pre-exposure prophylaxis, also known as PrEP. Providers and patients in gynecology clinics were interviewed and completed surveys to measure the feasibility and preference of prescribing PrEP.
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
Yes
University of Alabama at Birmingham
Birmingham, Alabama, United States
Start Date
September 22, 2023
Primary Completion Date
August 16, 2025
Completion Date
August 16, 2025
Last Updated
January 26, 2026
1,377
ACTUAL participants
PrEP acronym (pre-exposure prophylaxis)
BEHAVIORAL
Lead Sponsor
University of Alabama at Birmingham
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions